GTB-3650
- Generic Name
- GTB-3650
HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
Phase 1
Recruiting
- Conditions
- Myeloid MalignancyAcute Myeloid LeukemiaMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 45
- Registration Number
- NCT06594445
- Locations
- 🇺🇸
Masonic Cancer Center, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath